×
About 8,511 results

ALLMedicine™ Kidney Cancer Center

Research & Reviews  3,621 results

Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patie...
https://doi.org/10.1097/MD.0000000000025397
Medicine Kobayashi H, Tsuchiyama K et. al.

Apr 9th, 2021 - Decision-making to stop cancer treatment in patients with advanced cancer is stressful, and it significantly influences subsequent end-of-life palliative treatment. However, little is known about the extent to which the patient's self-decisions in...

Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
https://doi.org/10.1200/EDBK_320785
American Society of Clinical Oncology Educational Book. A... Schmidt AL, Tabakin AL et. al.

Apr 1st, 2021 - Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 inhibition or VEGF-targeted therapy. The new treatment paradigm that int...

see more →

Guidelines  37 results

Genetics of Renal Cell Carcinoma (PDQ®)–Health Professional Version
https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics
National Cancer Institute;

Mar 10th, 2021 - Renal cell carcinoma (RCC) is among the more commonly diagnosed cancers in both men and women. In the United States in 2021, about 76,080 cases of kidney cancer and renal pelvis cancer are expected to occur and lead to an estimated 13,780 deaths. ...

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and ...
https://doi.org/10.1016/j.kint.2020.06.046
Kidney International; Porta C, Bamias A et. al.

Oct 31st, 2020 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues ...

Diabetes and kidney cancer risk among post-menopausal women: The Iowa women’s health study
https://www.maturitas.org/article/S0378-5122(20)30341-8/fulltext
Maturitas Wang S

Aug 10th, 2020 - Many studies have reported a positive association between diabetes and kidney cancer. However, it is unclear whether diabetes is a risk factor for kidney cancer independent of other risk factors, such as obesity and hypertension. We comprehensivel...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to ...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 24th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followe...

see more →

Clinicaltrials.gov  4,277 results

Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patie...
https://doi.org/10.1097/MD.0000000000025397
Medicine Kobayashi H, Tsuchiyama K et. al.

Apr 9th, 2021 - Decision-making to stop cancer treatment in patients with advanced cancer is stressful, and it significantly influences subsequent end-of-life palliative treatment. However, little is known about the extent to which the patient's self-decisions in...

Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
https://doi.org/10.1200/EDBK_320785
American Society of Clinical Oncology Educational Book. A... Schmidt AL, Tabakin AL et. al.

Apr 1st, 2021 - Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 inhibition or VEGF-targeted therapy. The new treatment paradigm that int...

see more →

News  535 results

Genetics of Renal Cell Carcinoma (PDQ®)–Health Professional Version
https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics
National Cancer Institute;

Mar 10th, 2021 - Renal cell carcinoma (RCC) is among the more commonly diagnosed cancers in both men and women. In the United States in 2021, about 76,080 cases of kidney cancer and renal pelvis cancer are expected to occur and lead to an estimated 13,780 deaths. ...

Nivolumab-Cabozantinib Combo Boosts Survival Over Sunitinib in Kidney Cancer
https://www.medscape.com/viewarticle/946829

Mar 3rd, 2021 - NEW YORK (Reuters Health) - Previously untreated patients with advanced renal-cell carcinoma live twice as long without disease progression when given a combination of nivolumab and cabozantinib instead of sunitinib, according to results from the ...

Which Patients With Kidney Cancer Are Likely to Respond to ICI?
https://www.medscape.com/viewarticle/945382

Feb 4th, 2021 - Several factors associated with a diminished response to immune checkpoint inhibitor (ICI) drugs among patients with metastatic clear cell renal cell carcinoma (ccRCC) have been identified. They include the patient being aged 75 years or older, be...

ACE2-Generated Small Peptide Shows Promise in Clear Cell Kidney Cancer
https://www.medscape.com/viewarticle/944811

Jan 27th, 2021 - NEW YORK (Reuters Health) - Angiotensin-(1-7), a small peptide generated by angiotensin-converting enzyme 2 (ACE2), shows promise in combination with a programmed death-ligand 1 (PD-L1) pathway inhibitor and a vascular endothelial growth factor re...

see more →

Patient Education  41 results see all →